Trump Expected to Loosen Restrictions on Psychedelic Drugs

April 18, 2026 - 06:22

A new executive order is poised to significantly reduce federal restrictions on research involving psychedelic compounds. The directive aims to accelerate scientific studies into the potential efficacy of substances like psilocybin and MDMA for treating serious mental health conditions, including post-traumatic stress disorder (PTSD), depression, and anxiety.

This policy shift directs federal health agencies to streamline the often cumbersome application process for obtaining these Schedule I drugs for clinical trials. Proponents of the change argue that outdated regulatory hurdles have long stifled crucial medical research into these substances, despite growing anecdotal and preliminary scientific evidence of their therapeutic benefits. The order emphasizes a commitment to exploring all possible avenues to address the nation's ongoing mental health crisis.

The move is seen as a major step toward legitimizing the field of psychedelic-assisted therapy within the mainstream medical community. Researchers hope that reduced barriers will lead to larger, more definitive studies that could pave the way for future FDA approvals. While the substances would remain strictly controlled and illegal for general public use, this executive action marks a notable departure from decades of drug policy focused primarily on enforcement, signaling a new chapter focused on potential medical innovation.